BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32783629)

  • 1. Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer.
    Schumacher LD; Dal Pra A; Hoffe SE; Mellon EA
    Br J Radiol; 2020 Oct; 93(1114):20200028. PubMed ID: 32783629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
    de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
    Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation.
    Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Cambria R; Garibaldi C; Tagaste B; Vavassori A; Cattani F; Alterio D; Gherardi F; Serafini F; Rocco B; Musi G; De Cobelli O; Orecchia R
    Urol Oncol; 2011; 29(5):523-32. PubMed ID: 20005749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouse.
    Kersemans V; Beech JS; Gilchrist S; Kinchesh P; Allen PD; Thompson J; Gomes AL; D'Costa Z; Bird L; Tullis IDC; Newman RG; Corroyer-Dulmont A; Falzone N; Azad A; Vallis KA; Sansom OJ; Muschel RJ; Vojnovic B; Hill MA; Fokas E; Smart SC
    PLoS One; 2017; 12(4):e0176693. PubMed ID: 28453537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy.
    Nicosia L; Sicignano G; Rigo M; Figlia V; Cuccia F; De Simone A; Giaj-Levra N; Mazzola R; Naccarato S; Ricchetti F; Vitale C; Ruggieri R; Alongi F
    Acta Oncol; 2021 Feb; 60(2):215-221. PubMed ID: 32945701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy.
    Gill S; Thomas J; Fox C; Kron T; Rolfo A; Leahy M; Chander S; Williams S; Tai KH; Duchesne GM; Foroudi F
    Radiat Oncol; 2011 Oct; 6():145. PubMed ID: 22035354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost minimisation analysis: kilovoltage imaging with automated repositioning versus electronic portal imaging in image-guided radiotherapy for prostate cancer.
    Gill S; Younie S; Rolfo A; Thomas J; Siva S; Fox C; Kron T; Phillips D; Tai KH; Foroudi F
    Clin Oncol (R Coll Radiol); 2012 Oct; 24(8):e93-9. PubMed ID: 22694787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy for prostate cancer - Does daily image guidance with tighter margins improve patient reported outcomes compared to weekly orthogonal verified irradiation? Results from a randomized controlled trial.
    Tøndel H; Lund JÅ; Lydersen S; Wanderås AD; Aksnessæther B; Jensen CA; Kaasa S; Solberg A
    Radiother Oncol; 2018 Feb; 126(2):229-235. PubMed ID: 29398152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive image-guided radiotherapy (IGRT) eliminates the risk of biochemical failure caused by the bias of rectal distension in prostate cancer treatment planning: clinical evidence.
    Park SS; Yan D; McGrath S; Dilworth JT; Liang J; Ye H; Krauss DJ; Martinez AA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):947-52. PubMed ID: 22208964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early health economic analysis of 1.5 T MRI-guided radiotherapy for localized prostate cancer: Decision analytic modelling.
    Hehakaya C; van der Voort van Zyp JRN; Vanneste BGL; Grutters JPC; Grobbee DE; Verkooijen HM; Frederix GWJ
    Radiother Oncol; 2021 Aug; 161():74-82. PubMed ID: 34089754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Radiographers at the Helm: Moving Towards Radiographer-Led MR-Guided Radiotherapy.
    Hales RB; Rodgers J; Whiteside L; McDaid L; Berresford J; Budgell G; Choudhury A; Eccles CL
    J Med Imaging Radiat Sci; 2020 Sep; 51(3):364-372. PubMed ID: 32600981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer.
    Schaule J; Chamberlain M; Wilke L; Baumgartl M; Krayenbühl J; Zamburlini M; Mayinger M; Andratschke N; Tanadini-Lang S; Guckenberger M
    Radiat Oncol; 2021 Sep; 16(1):189. PubMed ID: 34565439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
    Leeman JE; Shin KY; Chen YH; Mak RH; Nguyen PL; D'Amico AV; Martin NE
    Cancer; 2023 Oct; 129(19):3044-3052. PubMed ID: 37485697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
    Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Image-guided intensity-modulated radiotherapy of prostate cancer: Analysis of interfractional errors and acute toxicity.
    Rudat V; Nour A; Hammoud M; Alaradi A; Mohammed A
    Strahlenther Onkol; 2016 Feb; 192(2):109-17. PubMed ID: 26545764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consideration of the likely benefit from implementation of prostate image-guided radiotherapy using current margin sizes: a radiobiological analysis.
    Tudor GS; Rimmer YL; Nguyen TB; Cowen MA; Thomas SJ
    Br J Radiol; 2012 Sep; 85(1017):1263-71. PubMed ID: 22337688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Dosimetric Comparison between Conventional Fractionated and Hypofractionated Image-guided Radiation Therapies for Localized Prostate Cancer.
    Li M; Li GF; Hou XY; Gao H; Xu YG; Zhao T
    Chin Med J (Engl); 2016 Jun; 129(12):1447-54. PubMed ID: 27270540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.